Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $4.9 million.

  • Stoke Therapeutics' Change in Accured Expenses rose 75166.89% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 616916.67%. This contributed to the annual value of $3.1 million for FY2024, which is 19625.94% up from last year.
  • Per Stoke Therapeutics' latest filing, its Change in Accured Expenses stood at $4.9 million for Q3 2025, which was up 75166.89% from $2.8 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Change in Accured Expenses high stood at $4.9 million for Q3 2025, and its period low was -$4.4 million during Q2 2023.
  • Moreover, its 4-year median value for Change in Accured Expenses was $351000.0 (2023), whereas its average is $582466.7.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 67738.69% in 2023, then surged by 75166.89% in 2025.
  • Stoke Therapeutics' Change in Accured Expenses (Quarter) stood at $199000.0 in 2022, then crashed by 677.39% to -$1.1 million in 2023, then soared by 289.64% to $2.2 million in 2024, then skyrocketed by 124.0% to $4.9 million in 2025.
  • Its Change in Accured Expenses stands at $4.9 million for Q3 2025, versus $2.8 million for Q2 2025 and $4.7 million for Q1 2025.